Related Experiment Video
Updated: Jan 13, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Severe community-acquired pneumonia: current concepts and controversies
Pierre-François Dequin1,2, Antoni Torres3, Matteo Bassetti4
1Inserm UMR 1100, Research Centre for Respiratory Diseases, University of Tours, Tours, France. pfdequin@gmail.com.
Abstract:
Community-acquired pneumonia, particularly in its severe forms (sCAP), remains a major public health problem due to its frequency, immediate and delayed complications, and the cost of treatment. Although rare, resistant pathogens could make it increasingly difficult to choose an empirical antibiotic treatment. Rapid molecular microbiological diagnostic techniques could help guide this choice, but their role needs to be better evaluated and their cost may be an obstacle to their widespread use. The duration of treatment tends to be decreasing, but could be guided by clinical progression and possibly biomarkers. As a disorder of dysregulated systemic inflammation, sCAP is potentially eligible for immunomodulatory treatment. Three recent high-powered randomized trials on corticosteroids have yielded conflicting results. There is a need to better define which patients are likely to benefit, perhaps those with a marked inflammatory syndrome, and in any case not those with influenza. Some macrolides also have a potential immunomodulatory effect. Other treatments are currently being investigated. Supportive care, particularly respiratory support, remains essential. It is not specific to sCAP and must be tailored to the severity of the patient's condition.
Insights
Severe community-acquired pneumonia (sCAP) presents significant public health challenges. Advances in diagnostics and immunomodulatory treatments offer potential improvements, but require further evaluation for optimal patient care.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Severe community-acquired pneumonia (sCAP) is a leading cause of morbidity and mortality, posing significant public health and economic burdens.
- The emergence of resistant pathogens complicates empirical antibiotic selection, highlighting the need for advanced diagnostic tools.
- sCAP involves dysregulated systemic inflammation, suggesting potential benefits from immunomodulatory therapies.
Purpose of the Study:
- To review current challenges and emerging strategies in managing severe community-acquired pneumonia (sCAP).
- To evaluate the role of rapid molecular diagnostics and novel therapeutic approaches in sCAP management.
- To discuss the potential and limitations of immunomodulatory treatments and supportive care in sCAP.
Main Methods:
- Literature review of recent high-powered randomized trials and clinical studies on sCAP management.
- Analysis of the impact of diagnostic technologies on treatment decisions.
- Evaluation of evidence for immunomodulatory agents and supportive care strategies.
Main Results:
- Conflicting results from recent corticosteroid trials necessitate better patient selection criteria, potentially identifying those with marked inflammatory syndromes.
- Rapid molecular diagnostics show promise for guiding antibiotic therapy but require further cost-effectiveness evaluation.
- Macrolides may possess immunomodulatory effects, and other novel treatments are under investigation.
- Optimizing respiratory support and tailoring supportive care remain critical.
Conclusions:
- Effective sCAP management requires a multifaceted approach, integrating advanced diagnostics, judicious antibiotic use, and potentially immunomodulatory therapies.
- Further research is needed to define optimal patient populations for immunomodulatory treatments and to validate novel therapeutic strategies.
- Personalized supportive care, especially respiratory support, remains a cornerstone of sCAP treatment.
More Related Videos
07:30Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:29Pneumonia II: Pathophysiology
01:28Acute Pyelonephritis II: Diagnostic Studies and Management